Top Ten 2024: Drug Pricing—340B Developments to Watch

• March 15, 2024

Based on AHLA’s annual Health Law Connections article, this special series brings together thought leaders from across the health law field to discuss the top ten issues of 2024. In the tenth episode, Sarah Bowman, Principal, PYA, speaks with Jolee H. Bollinger, Deputy General Counsel, Sharp HealthCare, and Andrew D. Ruskin, Partner, K&L Gates LLP, about potential 340B activity in 2024 as drug manufacturers continue to tighten access to 340B pricing. They discuss the impact of the Genesis case, how covered entities can navigate this uncertain environment and protect their access to 340B pricing, and trends pertaining to audits of covered entities. Sponsored by PYA.

+Watch   +Listen